Market revenue in 2023 | USD 2,749.4 million |
Market revenue in 2030 | USD 8,968.9 million |
Growth rate | 18.4% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Diagnostics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to precision medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 80.42% in 2023. Horizon Databook has segmented the UK precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The presence of sophisticated healthcare infrastructure, collaborations between key market players, and launch of novel products are anticipated to contribute to market growth in the UK. Government support & initiatives are expected to further propel the growth of the country’s precision medicine market in the coming years.
For instance, in 2020, the UK government issued GENOME UK: 2020 national genomic healthcare strategy, which focused on the strategies to improve genomics in healthcare and research. Similarly, in December 2018, Genomics plc, a UK-based company, raised funding of USD 40.3 million (EUR 37 million) for developing personalized medicine.
In January 2022, Eagle Genomics, a UK-based company, raised a funding of USD 20 million, which is aimed toward innovation in personalized medicine. In addition, in February 2024, an innovative AI-driven project, NextGen, was launched in the UK and EU to personalize therapies for cardiovascular disease patients.
Horizon Databook provides a detailed overview of country-level data and insights on the UK precision medicine market , including forecasts for subscribers. This country databook contains high-level insights into UK precision medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account